帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好，仅出现轻度胃肠道不良事件，并展现出有前景的活性，值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
HPV 相关口咽癌的免疫治疗
英文原题：Immunotherapy in HPV-Related Oropharyngeal Cancers.
查看英文原题
Immunotherapy in HPV-Related Oropharyngeal Cancers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近年来，人乳头瘤病毒（HPV）相关口咽鳞状细胞癌（OPSCC）的发病率持续上升。局部晚期HPV相关OPSCC的治疗包括多学科综合治疗。免疫检查点抑制剂免疫治疗用于复发/转移性头颈部鳞状细胞癌（HNSCC）患者的治疗，包括HPV相关OPSCC患者。关于HPV在肿瘤免疫微环境中作用的认识日益增多。因此，OPSCC的HPV状态在根治性治疗和转移性治疗背景下免疫治疗临床试验的设计中起着至关重要的作用。此外，HPV已成为潜在的治疗靶点，针对HPV的疫苗和过继性T细胞疗法正在开发用于OPSCC的治疗。多项新研究旨在将靶向HPV与免疫检查点抑制剂联合使用。因此，HPV相关OPSCC在免疫治疗时代仍然是一个独特的亚组。
展开英文摘要原文
Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) incidence has been increasing in recent decades. Treatment of the locally advanced HPV-related OPSCC includes a multidisciplinary approach. Immunotherapy with immune checkpoint inhibitors is used in the treatment of patients with recurrent/metastatic head and neck squamous cell carcinomas (HNSCC), including HPV-related OPSCC patients. There is increasing knowledge of the role of HPV in the tumor immune microenvironment.
Therefore, HPV status of OPSCC plays an essential role in the design of immunotherapy clinical trials in both curative intent and metastatic settings.
Moreover, HPV has become a potential therapeutic target, with vaccines and adoptive T-cell therapies being developed against HPV for the treatment of OPSCC. Several novel studies are designed to target HPV in combination with immune checkpoint inhibitors.
Thus, HPV-related OPSCC remains a unique subgroup in the immunotherapy era.
论文信息
- 作者
- Roof L、Yilmaz E
- 第一作者单位
- Department of Hematology & Medical Oncology, Cleveland Clinic Taussig Cancer Institute, 10201 Carnegie Avenue, CA Building CA 6-150, Cleveland, OH, 44106, USA.United States
- 通讯作者单位
- Department of Hematology & Medical Oncology, Cleveland Clinic Taussig Cancer Institute, 10201 Carnegie Avenue, CA Building CA 6-150, Cleveland, OH, 44106, USA. yilmaze@ccf.org.United States
- 文献类型
- 综述
- 期刊
- Current treatment options in oncology2023 Mar
- 原文标识
- PubMed 36719604 · DOI 10.1007/s11864-023-01050-x
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →